Literature DB >> 19473409

Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance.

V Terraube1, J S O'Donnell, P V Jenkins.   

Abstract

The interaction of factor VIII (FVIII) with von Willebrand Factor (VWF) is of direct clinical significance in the diagnosis and treatment of patients with haemophilia A and von Willebrand disease (VWD). A normal haemostatic response to vascular injury requires both FVIII and VWF. It is well-established that in addition to its role in mediating platelet to platelet and platelet to matrix binding, VWF has a direct role in thrombin and fibrin generation by acting as a carrier molecule for the cofactor FVIII. Recent studies show that the interaction affects not only the biology of both FVIII and VWF, and the pathology of haemophilia and VWD, but also presents opportunities in the treatment of haemophilia. This review details the mechanisms and the molecular determinants of FVIII interaction with VWF, and the role of FVIII-VWF interaction in modulating FVIII interactions with other proteases, cell types and cellular receptors. The effect of defective interaction of FVIII with VWF as a result of mutations in either protein is discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473409     DOI: 10.1111/j.1365-2516.2009.02005.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  49 in total

1.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Authors:  Ekta Seth Chhabra; Tongyao Liu; John Kulman; Susannah Patarroyo-White; Buyue Yang; Qi Lu; Douglas Drager; Nancy Moore; Jiayun Liu; Amy M Holthaus; Jurg M Sommer; Ayman Ismail; Deana Rabinovich; Zhan Liu; Arjan van der Flier; Allison Goodman; Chris Furcht; Mark Tie; Tyler Carlage; Randy Mauldin; Terrence M Dobrowsky; Zhiqian Liu; Oblaise Mercury; Lily Zhu; Baisong Mei; Volker Schellenberger; Haiyan Jiang; Glenn F Pierce; Joe Salas; Robert Peters
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

2.  Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

Authors:  Annarita Tagliaferri; Annalisa Matichecchia; Gianna F Rivolta; Federica Riccardi; Gabriele Quintavalle; Anna Benegiamo; Rossana Rossi; Antonio Coppola
Journal:  Blood Transfus       Date:  2019-11-04       Impact factor: 3.443

3.  Role of bone marrow transplantation for correcting hemophilia A in mice.

Authors:  Antonia Follenzi; Sanj Raut; Simone Merlin; Rita Sarkar; Sanjeev Gupta
Journal:  Blood       Date:  2012-02-24       Impact factor: 22.113

Review 4.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

Review 5.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

6.  Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Authors:  Judicael Fazavana; Teresa M Brophy; Alain Chion; Niamh Cooke; Virginie Terraube; Justin Cohen; Chuenlei Parng; Debra Pittman; Orla Cunningham; Matthew Lambert; James S O'Donnell; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

Review 7.  Treatment Options in Hemophilia.

Authors:  Wolfgang Miesbach; Joachim Schwäble; Markus M Müller; Erhard Seifried
Journal:  Dtsch Arztebl Int       Date:  2019-11-22       Impact factor: 5.594

8.  Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Authors:  Wojciech Jankowski; Yara Park; Joseph McGill; Eugene Maraskovsky; Marco Hofmann; Vincent P Diego; Bernadette W Luu; Tom E Howard; Roberta Kellerman; Nigel S Key; Zuben E Sauna
Journal:  Blood Adv       Date:  2019-05-14

9.  Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis.

Authors:  Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider
Journal:  J Rheumatol       Date:  2019-08-01       Impact factor: 4.666

Review 10.  Impact of notch signaling on inflammatory responses in cardiovascular disorders.

Authors:  Thibaut Quillard; Beatrice Charreau
Journal:  Int J Mol Sci       Date:  2013-03-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.